| Literature DB >> 35169144 |
Chen-Xiong Hsu1,2, Kuan-Heng Lin1,2,3, Shan-Ying Wang1,4, Wei-Ta Tsai1, Chiu-Han Chang2, Hui-Ju Tien1,2, Pei-Wei Shueng5,6, Tung-Hsin Wu7, Greta S P Mok8.
Abstract
Radiotherapy treatment planning (RTP) is time-consuming and labor-intensive since medical physicists must devise treatment plans carefully to reduce damage to tissues and organs for patients. Previously, we proposed the volume-based algorithm (VBA) method, providing optimal partial arcs (OPA) angle to achieve the low-dose volume of lungs in dynamic arc radiotherapy. This study aimed to implement the VBA for esophageal cancer (EC) patients and compare the lung dose and delivery time between full arcs (FA) without using VBA and OPA angle using VBA in volumetric modulated arc therapy (VMAT) plans. We retrospectively included 30 patients diagnosed with EC. RTP of each patient was replanned to 4 VMAT plans, including FA plans without (FA-C) and with (FA + C) dose constraints of OARs and OPA plans without (OPA-C) and with (OPA + C) dose constraints of OARs. The prescribed dose was 45 Gy. The OARs included the lungs, heart, and spinal cord. The dose distribution, dose-volume histogram, monitor units (MUs), delivery time, and gamma passing rates were analyzed. The results showed that the lung V5 and V10 in OPA + C plans were significantly lower than in FA + C plans (p < 0.05). No significant differences were noted in planning target volume (PTV) coverage, lung V15, lung V20, mean lung dose, heart V30, heart V40, mean heart dose, and maximal spinal cord dose between FA + C and OPA + C plans. The delivery time was significantly longer in FA + C plans than in OPA + C plans (237 vs. 192 s, p < 0.05). There were no significant differences between FA + C and OPA + C plans in gamma passing rates. We successfully applied the OPA angle based on the VBA to clinical EC patients and simplified the arc angle selection in RTP. The VBA could provide a personalized OPA angle for each patient and effectively reduce lung V5, V10, and delivery time in VMAT.Entities:
Mesh:
Year: 2022 PMID: 35169144 PMCID: PMC8847643 DOI: 10.1038/s41598-021-04571-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flowchart of study design.
Figure 2Sample patient for calculating the OPA angle in VBA. The axial and coronal views are shown on the VBA interface. The PTV (red area), length and width of PTV, lung volume, and the expected lung V5 were shown as input. When the lung V5 was less than 55%, the θA was 110° (solid red line), indicating an OPA angle of 110° for this patient. The pink area is restricted volume.
Characteristics of EC patients in this study.
| Characteristics | n = 30 | |
|---|---|---|
| Sex | Male | 20 |
| Female | 10 | |
| Age (years) | Median | 56 |
| Range | 43–78 | |
| Length of tumor (cm) | Median | 18.65 |
| Range | 6.30–25.20 | |
| PTV (cm3) | Median | 769.80 |
| Range | 281.53–1234.78 | |
| Location of tumor | Upper | 3 |
| Middle | 20 | |
| Lower | 7 | |
| T | 1 | 15 |
| 2 | 9 | |
| 3 | 6 | |
| N | 0 | 10 |
| + | 20 | |
| M | 0 | 29 |
| 1 | 1 | |
| AJCC stage | I | 14 |
| II | 8 | |
| III | 7 | |
| IV | 1 | |
PTV planning target volume.
Figure 3The isodose curves and DVH of VMAT plans for a patient. For this patient, the OPA angle was 110°. (a) Isodose curves of FA + C plan. (b) Isodose curves of OPA + C plan. (c) DVH for FA + C and OPA + C plan. The gantry arc angles were shown in (a) and (b). The red arcs were counterclockwise (CCW) direction. The green arcs were clockwise (CW) direction. The FA plans used two full arcs. The OPA plans used six partial arcs. The red line means the relative lung volume receiving more than 5 Gy (V5) in DVH of (c).
Figure 4The range of OPA angles was from 80° to 310° for 30 patients. The OPA angle could be calculated using VBA for each patient.
Comparison of dosimetric factors between FA + C and OPA + C plans.
| Parameter | FA + C | OPA + C | ||
|---|---|---|---|---|
| PTV | D5 (Gy) | 46.88 ± 6.99 | 47.53 ± 7.49 | 0.539 |
| D95 (Gy) | 43.31 ± 6.99 | 43.29 ± 7.09 | 0.976 | |
| HI | 1.08 ± 0.03 | 1.10 ± 0.04 | 0.159 | |
| CI | 1.15 ± 0.18 | 1.18 ± 0.16 | 0.375 | |
| Whole lung | Mean dose (Gy) | 10.37 ± 1.67 | 9.87 ± 1.82 | 0.252 |
| V20 (%) | 18.11 ± 4.09 | 17.14 ± 4.03 | 0.414 | |
| V15 (%) | 23.75 ± 4.51 | 21.77 ± 4.57 | 0.094 | |
| V10 (%) | 30.89 ± 5.07 | 28.05 ± 5.59 | 0.041* | |
| V5 (%) | 48.55 ± 6.82 | 43.38 ± 8.22 | 0.005* | |
| Right lung | Mean dose (Gy) | 9.81 ± 2.04 | 9.22 ± 2.16 | 0.237 |
| V20 (%) | 16.75 ± 5.08 | 15.79 ± 5.02 | 0.454 | |
| V15 (%) | 21.79 ± 5.70 | 20.00 ± 5.62 | 0.219 | |
| V10 (%) | 29.25 ± 6.70 | 26.07 ± 6.72 | 0.041* | |
| V5 (%) | 45.71 ± 8.81 | 40.79 ± 9.09 | 0.015* | |
| Left lung | Mean dose (Gy) | 10.95 ± 2.03 | 10.62 ± 2.21 | 0.706 |
| V20 (%) | 19.25 ± 5.51 | 18.82 ± 5.04 | 0.689 | |
| V15 (%) | 24.93 ± 5.52 | 23.75 ± 6.02 | 0.553 | |
| V10 (%) | 32.79 ± 6.13 | 30.18 ± 7.00 | 0.149 | |
| V5 (%) | 50.46 ± 7.16 | 46.11 ± 9.77 | 0.033* | |
| Heart | Mean dose (Gy) | 20.76 ± 8.25 | 21.37 ± 8.30 | 0.813 |
| V40 (%) | 12.54 ± 10.30 | 13.64 ± 10.45 | 0.728 | |
| V30 (%) | 29.21 ± 17.63 | 30.96 ± 17.22 | 0.695 | |
| Spinal cord | Maximum dose (Gy) | 36.92 ± 6.16 | 39.19 ± 5.07 | 0.193 |
FA + C full arcs plans with constraints, OPA + C optimal partial arcs plans with constraints, PTV planning target volume, CI conformity index, HI heterogeneity index.
*Represents significant difference (p < 0.05).
The MUs and delivery time in FA + C and OPA + C plans.
| Parameter | FA + C | OPA + C | |
|---|---|---|---|
| MUs | 673 ± 183 | 605 ± 139 | 0.075 |
| Delivery time (s) | 237 ± 8 | 192 ± 37 | 0.000* |
| Gamma passing rate (%) | 97.67 ± 1.09 | 96.17 ± 0.75 | 0.139 |
FA + C full arcs plans with constraints, OPA + C optimal arcs plans with constraints, MU monitor unit, s second.
*Represents significant difference (p < 0.05).